

# Azerbaijan

Population 2016

9.7 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.62 (0.61–0.63)	6.4 (6.3–6.5)
Mortality (HIV+TB only)	0.028 (0.02–0.036)	0.28 (0.2–0.37)
Incidence (includes HIV+TB)	6.4 (4.9–8.2)	66 (51–84)
Incidence (HIV+TB only)	0.13 (0.083–0.18)	1.3 (0.86–1.9)
Incidence (MDR/RR-TB)**	2.4 (2–2.9)	25 (20–30)

Estimated TB incidence by age and sex (thousands)*, 2016			
	0-14 years	> 14 years	Total
Females	0.35 (0.27–0.44)	1.8 (1.4–2.3)	2.2 (1.6–2.7)
Males	0.4 (0.3–0.5)	3.9 (2.9–4.9)	4.3 (3.2–5.4)
Total	0.76 (0.57–0.94)	5.7 (4.3–7.1)	6.4 (4.9–8.2)

TB case notifications, 2016	
Total cases notified	6 707
Total new and relapse	5 159
- % tested with rapid diagnostics at time of diagnosis	39%
- % with known HIV status	70%
- % pulmonary	80%
- % bacteriologically confirmed among pulmonary	61%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	80% (63–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.1 (0.08–0.13)

TB/HIV care in new and relapse TB patients, 2016		
	Number	(%)
Patients with known HIV-status who are HIV-positive	99	2%
- on antiretroviral therapy	78	79%

Drug-resistant TB care, 2016			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 500 (1 400–1 600)
Estimated % of TB cases with MDR/RR-TB	13% (10–16)	39% (37–42)	
% notified tested for rifampicin resistance	31%	61%	2 955
MDR/RR-TB cases tested for resistance to second-line drugs			589
Laboratory-confirmed cases		MDR/RR-TB: 925, XDR-TB: 77	
Patients started on treatment ****		MDR/RR-TB: 798, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New cases registered in 2015	83%	1 475
Previously treated cases registered in 2015	73%	2 738
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014	59%	745
XDR-TB cases started on second-line treatment in 2014	23%	69

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	60%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	86% (63–100)

TB financing, 2017	
National TB budget (US\$ millions)	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases  
— Previously treated cases  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

